Sagres Discovery

Sagres Discovery was a functional genomics company focused on the discovery and validation of novel oncology targets. The company utilized its proprietary OncoTag platform, which employed insertional mutagenesis in mice to rapidly identify genes linked to cancer development. By analyzing these genetic tags, Sagres identified hundreds of potential oncogenes and tumor suppressors to build a comprehensive database of validated targets. The company's business model centered on leveraging this target suite to support the development of small molecule and antibody-based therapeutics. Sagres was acquired by Chiron Corporation in 2004 to bolster Chiron's oncology pipeline and target discovery capabilities.